Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib With or Without Abexinostat in Advanced or Metastatic Renal Cell Carcinoma
2018-001495-38Phase 3Terminated
- Sponsor
- Xynomic Pharmaceuticals
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing pazopanib + abexinostat with pazopanib + placebo (2 arms). Primary endpoint: Progression-free survival (blinded IRC assessment). Started Dec 2018; status: terminated.
02
Drugs
abexinostat
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2018-001495-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001495-38.